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This method uses the life table data directly to derive an empiric distribution of 
death times. Additionally, parametric survival analysis may be used to fit life table 
data. This method may be more flexible, avoiding the need to look up mortality 
hazards directly from life tables, requiring fewer parameters, and possibly sav-
ing computation time. Typically, this method is carried out by linearizing specific 
parametric survival distributions and using regression analysis on data from the 
life table to obtain estimates for the parameters of the distribution. Although this 
type of analysis is fairly straightforward, the estimates of the uncertainty around 
the parameters are inaccurate. A new method of obtaining these parameters, which 
involves simulating individual death times from the life table data and using maxi-
mum likelihood estimation to obtain the needed parameters, may be considered 
when modeling all-cause mortality. Utilizing the number of individuals at risk, this 
method may provide more accurate estimates of parameters and their uncertainty. 
The implementation, appropriateness, challenges, advantages and disadvantages 
of these three techniques when modeling all-cause mortality in health economic 
models will be discussed.
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Networks of treatments summarize all available information about the relative 
effectiveness of several treatments, also if both direct and indirect evidence needs to 
be combined[1]. For clinical trials with survival results, some will have been reported 
based on numbers of patients with event, and some based on the hazard ratio. A 
common scale for mapping the observed effects has been proposed[2]. Treatment 
contrasts would then be estimated through Bayesian methodology based on Markov 
Chain Monte Carlo (MCMC) simulation. Similar problems arise for trials with binary 
outcome. We investigate one example from pulmology and compare two imple-
mentations of the MCMC method, WinBUGS and SAS® PROC MCMC. Moreover, we 
investigate a deterministic-numerical approximation to the distribution of treat-
ment contrasts, the integrated nested Laplace approximation (INLA) method. Of 
particular interest here is the goodness of the approximation, as the example 
dataset includes only small numbers of trials, patients and events. We show how 
to condense graphically the complex pattern of multiple treatment comparisons. 
We conclude with remarks on model selection, goodness-of-fit and the Deviance 
Information Criterion (DIC).
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Objectives: Meta-analysis is being conducted extensively in part due to require-
ments from health care decision-making agencies. Meta-analysis techniques con-
tinue to develop, and software now exists to model networks using Bayesian or 
frequentist approaches with study effects treated as fixed or random. The non-
model based anchored indirect-treatment comparison (AIC) method is also suit-
able for making pairwise treatment comparisons. However, practical issues emerge 
particularly when the network is comprised of a limited number of studies. Of 
special interest is the situation where a star network contains only one trial for 
a given treatment comparison. Our goal was to investigate the performance and 
interpretation of different meta-analysis methods when few studies are availa-
ble. MethOds: Example star networks anchored by placebo were created for binary 
endpoints with varying proportions and sample sizes. Generalized linear mixed 
models were fitted using PROC GLIMMIX in SAS with a random study effect. Results 
were compared to the AIC method as well as analogous Bayesian models using 
WinBUGS. Results: Estimated odds ratios were examined to identify patterns 
among methods. If placebo effects were largely different across individual trials, 
differences between methods varied depending on effect sizes and sample sizes. If 
placebo effects were similar, the frequentist random-effects model was not able to 
estimate a random study effect and it was reduced to a fixed-effect model (similar 
to the AIC). cOnclusiOns: The limitations of conducting a meta-analysis with a 
small number of trials should be understood regardless of the methodology used. In 
the special case of a star network with only one trial per treatment comparison, the 
differences between methods depend on the underlying evidence. The implications 
for interpretation will be discussed.
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Objectives: Economic evaluations in oncology built using partitioned survival 
analysis do not permit analysis of the post-progression period separately from the 
progression-free period. Moreover, when the outcomes are not complete at the 
time of the analysis, the benefits experienced by patients in the clinical trial used 
to inform the model are assumed to continue for the duration of the model due 
to extrapolation of the trial data using one set of parametric curves. The objective 
of this study is to present and contrast possible methods to address the struc-
tural uncertainty in the incremental effects and the cost-effectiveness estimates 
derived from partitioned survival models. MethOds: Options for addressing the 
long-term benefits in partitioned survival models are explored using a hypotheti-
cal economic model with three states (progression-free, progressed disease, and 
death). The methods include the standard approach of projecting treatment group 
PFS and OS outcomes using parametric survival curves, using time-varying hazard 
ratios to modify the relative benefits between treatments, calculating and modi-
fying treatment-related Markov probabilities following progression in the cohort, 
the framework is flexible enough to capture treatment effects that vary by line of 
therapy, and we demonstrate how appropriate discounting to allow for differential 
timing can still be made. We believe that the framework illustrated in this paper 
has wide applicability to sequencing models in many disease areas, most nota-
bly oncology and rheumatology where such sequencing models are common. We 
demonstrate the flexibility of the approach and show how time dependency can be 
incorporated at any sequence of the model without having to resort to individual 
patient simualation.
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Rare diseases provide a perplexing problem for reimbursement agencies. Orphan 
drug development is often incentivized by government entities. Despite these 
incentives, reimbursement at a viable level is not assured, and recent efforts by 
reimbursement bodies are changing the reimbursement paradigm substantially. 
Value-based pricing agreements, which link the price of the drug to the value 
achieved, is one such effort. However, demonstrating value for an orphan drug 
remains challenging. To better understand the potential value and therefore pricing 
of orphan drugs, we developed a comprehensive model to evaluate the pricing, eco-
nomics, reimbursement, and market strategy (PERMS) specifically for these drugs. 
The interactive simulation model was developed to combine evidence on develop-
ment costs, cost-effectiveness, treatment pathways, improvements in quality of 
life, and market share. The PERMS model was designed to evolve alongside the 
drug development process, incorporating new parameters and data as they become 
known. Extensive sensitivity analyses are performed to highlight the substantial 
uncertainty in disease prevalence and costs of the diseases. An interactive inter-
face is developed for users to examine how changes in model input values affect 
outcomes of interest. In this presentation, we will describe the primary elements 
of the PERMS model, demonstrate how the results may vary across subpopulations 
and illustrate the potential value of new drugs. Concepts will be illustrated through 
the use of real-world examples such as graft-versus-host disease (GVHD); a major 
complication of stem cell or bone marrow transplantation that has significant prog-
nostic implications in the setting of a rare resource. This presentation will illustrate 
how a holistic view through simulation modeling can be useful and informative for 
understanding disease burden and potential reimbursement levels and making a 
decision to proceed to the next phase of drug development.
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Objectives: To demonstrate how a conceptual model of symptoms of non-diabetic 
peripheral neuropathic pain, impact on quality of life and tolerability of treatments 
helps to select patient reported outcomes (PROs) in clinical trials. To show that 
the selected PROs measure what is expected. MethOds: A literature review and 
interviews with 4 clinical experts were conducted to identify the PRO measurement 
concepts related to symptoms and impacts of highest importance and relevance 
to non-diabetic peripheral neuropathic pain patients. The mechanism of action 
of treatments available and in development were also included in the conceptual 
model. Based on this information, available instruments were evaluated to assess 
if measures focusing on emerging, central concepts were available and of relevance 
to a planned Phase IV study. Results: Based on the literature review and expert 
interviews, pain was the predominant symptom concept. The most predominant 
impact concepts were difficulty with sleep quantity and quality. Available treat-
ments suggested detrimental impact on cognition and local treatment-related 
pain. Instruments that seem to measure the central concepts were numerical pain 
rating scale scale (NPRS), MOS-Sleep and MOS-Cog. Furthermore the Treatment 
Satisfaction Questionnaire for Medication (TSQM) was assessed in order to be able 
to measure treatment satisfaction comparing different medications Results of the 
chosen PROs included in a Phase IV study with patients with non-diabetic peripheral 
neuropathic pain seem to show that they are able to measure the concepts they 
were selected to assess. cOnclusiOns: The FDA PRO Guidance states that meas-
ures should be conceptually valid as they relate to the disease being studied, meet 
a threshold of psychometric soundness, and be relevant to patients. This research 
represents an important step toward establishing the PROs that could be used in 
studies with patients with non-diabetic peripheral neuropathic pain.
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The estimation of life-years is an important component of many health economic 
models and this outcome is often required by health technology assessment agen-
cies in the evaluation of health care technologies. Life-years are often obtained 
by adjusting the country-, age-, and gender-specific all-cause mortality, which 
considers all deaths in a population regardless of the cause, to account for addi-
tional deaths due to a specific disease (i.e., the disease-specific mortality). Properly 
modeling all-cause mortality and knowing the uncertainty associated with the 
estimates (if estimated) is therefore an important step in building a health eco-
nomic model. The report of the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) Modeling Good Research Practices Task Force recom-
mends modeling all-cause mortality non-parametrically based on life table data. 
